U.K’s NICE To Help Build India’s Health Technology Assessment Board
This article was originally published in PharmAsia News
India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.
You may also be interested in...
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.